In this study, we provided statistically significant evidence that MGA mutation was a favorable prognostic biomarker for ICI treatment outcome, which was independent of TMB, PD-L1 expression, and other ICI-related mutations only for patients with LUAD but not for those with LUSC or other common type of cancers. This evidence concerns the gene MGA and cancer.